World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   1007 records for 274 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7 8 9 10 Last
Recruitment statusMain ID Public TitleDate of Registration
RecruitingCTRI/2014/04/004518
To assess long term efficacy, safety, tolerability and usability of Secukinumab in patients with active Rheumatid Artheritis
02-04-2014
AuthorisedEUCTR2013-001939-47-IT
Reformulated raltegravir (1200 mg) once a day versus raltegravir (400 mg) twice a day in treatment-naïve patients
28/02/2014
AuthorisedEUCTR2013-003331-30-AT
A study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-003331-30-FIA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.18/02/2014
AuthorisedEUCTR2013-003331-30-ITA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.18/02/2014
AuthorisedEUCTR2013-003331-30-NLA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.04/03/2014
AuthorisedEUCTR2013-003331-30-DEA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.25/02/2014
AuthorisedEUCTR2013-003331-30-ESA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.07/03/2014
AuthorisedEUCTR2013-003331-30-PTA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.25/02/2014
AuthorisedEUCTR2013-003331-30-PLA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.12/03/2014
17/02/2014
Not recruitingNCT02044107
The Effectiveness of Co-packaging With Zinc to Improve Treatment of Diarrhea and Pneumonia in Guatemala
21/01/2014
RecruitingNCT02040766
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 5-11 Years Old With Persistent Asthma
16/01/2014
RecruitingNCT02019420
TR-701 FA vs Linezolid for the Treatment of Nosocomial Pneumonia
18/12/2013
AuthorisedEUCTR2013-003390-95-GB
A Study of Gantenerumab in Patients with Mild Alzheimer Disease
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-003390-95-ESA Study of Gantenerumab in Patients with Mild Alzheimer Disease27/12/2013
AuthorisedEUCTR2013-003390-95-PTA Study of Gantenerumab in Patients with Mild Alzheimer Disease30/12/2013
AuthorisedEUCTR2013-003390-95-SEA Study of Gantenerumab in Patients with Mild Alzheimer Disease19/12/2013
AuthorisedEUCTR2013-003390-95-HUA Study of Gantenerumab in Patients with Mild Alzheimer Disease06/02/2014
AuthorisedEUCTR2013-003390-95-NLA Study of Gantenerumab in Patients with Mild Alzheimer Disease14/01/2014
AuthorisedEUCTR2013-003390-95-ITA Study of Gantenerumab in Patients with Mild Alzheimer Disease08/01/2014
AuthorisedEUCTR2013-003390-95-DEA Study of Gantenerumab in Patients with Mild Alzheimer Disease17/12/2013
RecruitingNCT02051608A Study of Gantenerumab in Patients With Mild Alzheimer Disease30/01/2014
10/12/2013
RecruitingNCT02008344
Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults
08/12/2013
AuthorisedEUCTR2013-003434-32-NL
A long-term study of the efficacy and safety of secukinumab compared with ustekinumab in adult subjects with moderate to severe plaque psoriasis
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-003434-32-ESA long-term study of the efficacy and safety of secukinumab compared with ustekinumab in adult subjects with moderate to severe plaque psoriasis13/12/2013
AuthorisedEUCTR2013-003434-32-SKA long-term study of the efficacy and safety of secukinumab compared with ustekinumab in adult subjects with moderate to severe plaque psoriasis08/01/2014
AuthorisedEUCTR2013-003434-32-DEA long-term study of the efficacy and safety of secukinumab compared with ustekinumab in adult subjects with moderate to severe plaque psoriasis23/12/2013
AuthorisedEUCTR2013-003434-32-HUA long-term study of the efficacy and safety of secukinumab compared with ustekinumab in adult subjects with moderate to severe plaque psoriasis16/01/2014
AuthorisedEUCTR2013-003434-32-ATA long-term study of the efficacy and safety of secukinumab compared with ustekinumab in adult subjects with moderate to severe plaque psoriasis23/12/2013
AuthorisedEUCTR2013-003434-32-GBA long-term study of the efficacy and safety of secukinumab compared with ustekinumab in adult subjects with moderate to severe plaque psoriasis23/12/2013
AuthorisedEUCTR2013-003434-32-EEA long-term study of the efficacy and safety of secukinumab compared with ustekinumab in adult subjects with moderate to severe plaque psoriasis13/02/2014
AuthorisedEUCTR2013-003434-32-PTA long-term study of the efficacy and safety of secukinumab compared with ustekinumab in adult subjects with moderate to severe plaque psoriasis30/12/2013
AuthorisedEUCTR2013-003434-32-GRA long-term study of the efficacy and safety of secukinumab compared with ustekinumab in adult subjects with moderate to severe plaque psoriasis21/01/2014
AuthorisedEUCTR2013-003434-32-DKA long-term study of the efficacy and safety of secukinumab compared with ustekinumab in adult subjects with moderate to severe plaque psoriasis03/04/2014
AuthorisedEUCTR2013-003434-32-BGA long-term study of the efficacy and safety of secukinumab compared with ustekinumab in adult subjects with moderate to severe plaque psoriasis20/03/2014
RecruitingNCT02074982Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis27/02/2014
06/12/2013
RecruitingNCT02008227
A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "OAK"
06/12/2013
    
1 2 3 4 5 6 7 8 9 10 Last
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history